Home|Journals|Articles by Year|Audio Abstracts
 

Research Article



Polymeric nanoparticle of Ebastine: Formulation, Characterization and in vitro Evaluation

Hajer Sh*. Ali, Nawal A. Rajab.




Abstract

The main aim of this research work was the development and evaluation of polymeric nanoparticle for the bioavailability improvement of Ebastine (EBT) to treat allergic condition. EBT is a piperidine derivative that binds preferentially to peripheral H1 receptors and is a long-acting, non-sedating second-generation histamine receptor antagonist. It is practically insoluble in water (class II, according to BCS). This work aims to formulate and adjust Ebastine polymeric nanoparticles to improve the EBT solubility as well as dissolution rate. For the synthesis of PNPs, the solvent evaporation technique was used, and three different types of stabilizer that used (HPMC E5, Soluplus, tween 80). The particle size analysis indicated that the optimized formula EBT 9 had a reduced nanoparticulate size of 42 nm, with a 90 percent increase in in-vitro dissolution profile compared to 17 percent for the comparison Ebastine powder in 0.1 N HCl media (pH 1.2). As a result, polymeric nanoparticles formulation of weakly water soluble EBS greatly improved the drug's dissolving rate and increased its solubility.

Key words: Polymeric nanoparticles (PNPs), Evaluation, Preparation, Delivery.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.